ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.23
-0.98%
US Tech 100
20,530.00
-3.09%
S&P 500
5,983.01
-1.94%
US Dollar vs CAD
1.43914
-0.67%
Bitcoin
99,390.02
-5.04%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Share Price

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
1.47
-0.04
( -2.65% )
Updated: 11:39:11
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.47
Bid
1.47
Ask
1.48
Volume
465,573
1.47 Day's Range 1.5395
1.45 52 Week Range 8.33
Market Cap
133.112M
Previous Close
1.51
Open
1.48
Last Trade
86
@
1.475
Last Trade Time
11:39:16
Financial Volume
US$ 692,388
VWAP
1.4872
Average Volume (3m)
1,611,568
Shares Outstanding
90,552,687
Dividend Yield
-
PE Ratio
-1.31
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was US$1.51. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 1.45 to US$ 8.33.

Caribou Biosciences currently has 90,552,687 shares outstanding. The market capitalization of Caribou Biosciences is US$136.73 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.31.

Ask ADVFN Intelligence (AI)

CRBU Latest News

More News

The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, Jan. 27, 2025 NEW YORK, Jan. 27, 2025...

7 hours ago
PR Newswire (US)

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc.(CRBU) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc.(CRBU) Shareholders PR Newswire NEW YORK, Jan. 23, 2025 NEW YORK, Jan. 23, 2025...

January 23 2025
PR Newswire (US)

Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CRBU

Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CRBU PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK , Jan. 20, 2025...

January 20 2025
PR Newswire (US)

CRBU LAWSUIT ALERT: The Gross Law Firm Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

CRBU LAWSUIT ALERT: The Gross Law Firm Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025...

January 16 2025
PR Newswire (US)

Form 8-K - Current report

January 13 2025
Edgar (US Regulatory)

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan. 13, 2025...

January 13 2025
PR Newswire (US)

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L...

January 12 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

January 10 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

January 10 2025
Edgar (US Regulatory)

Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/...

January 09 2025
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1002-6.381352693921.57021.581.4511308141.51847468CS
4-0.18-10.90909090911.652.041.4515323731.6324442CS
12-0.74-33.48416289592.212.99951.4516115682.01752984CS
26-1.08-42.35294117652.552.99951.4512376072.00366842CS
52-3.99-73.07692307695.468.331.4516691383.07506231CS
156-8.91-85.83815028910.3813.191.4513337025.13067452CS
260-16.18-91.67138810217.6532.6451.4512323996.35485284CS

CRBU - Frequently Asked Questions (FAQ)

What is the current Caribou Biosciences share price?
The current share price of Caribou Biosciences is US$ 1.47
How many Caribou Biosciences shares are in issue?
Caribou Biosciences has 90,552,687 shares in issue
What is the market cap of Caribou Biosciences?
The market capitalisation of Caribou Biosciences is USD 136.73M
What is the 1 year trading range for Caribou Biosciences share price?
Caribou Biosciences has traded in the range of US$ 1.45 to US$ 8.33 during the past year
What is the PE ratio of Caribou Biosciences?
The price to earnings ratio of Caribou Biosciences is -1.31
What is the cash to sales ratio of Caribou Biosciences?
The cash to sales ratio of Caribou Biosciences is 3.89
What is the reporting currency for Caribou Biosciences?
Caribou Biosciences reports financial results in USD
What is the latest annual turnover for Caribou Biosciences?
The latest annual turnover of Caribou Biosciences is USD 34.48M
What is the latest annual profit for Caribou Biosciences?
The latest annual profit of Caribou Biosciences is USD -102.07M
What is the registered address of Caribou Biosciences?
The registered address for Caribou Biosciences is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Caribou Biosciences website address?
The website address for Caribou Biosciences is www.cariboubio.com
Which industry sector does Caribou Biosciences operate in?
Caribou Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
YIBOPlanet Image International Ltd
US$ 7.97
(270.70%)
20.97M
JGAurora Mobile Ltd
US$ 13.716
(128.14%)
25.21M
AKROAkero Therapeutics Inc
US$ 53.08
(102.75%)
10.87M
HWHHWH International Inc
US$ 0.561
(94.99%)
357.23M
ORKTOrangeKloud Technology Inc
US$ 1.15
(66.67%)
13.95M
ALLKAllakos Inc
US$ 0.2505
(-79.30%)
29.83M
NXUNXU Inc
US$ 0.2971
(-51.77%)
7.3M
VERUVeru Inc
US$ 0.5924
(-51.04%)
32.74M
WOKWORK Medical Technology Group Ltd
US$ 2.78
(-42.32%)
691.71k
NBISNebius Group NV
US$ 26.915
(-35.44%)
28.01M
NVDANVIDIA Corporation
US$ 120.72
(-15.36%)
460.76M
HWHHWH International Inc
US$ 0.5567
(93.50%)
357.26M
ONCOOnconetix Inc
US$ 0.6849
(42.69%)
174.45M
HOLOMicroCloud Hologram Inc
US$ 1.83
(18.06%)
169.61M
RGTIRigetti Computing Inc
US$ 12.49
(-5.38%)
95.15M

CRBU Discussion

View Posts
Monksdream Monksdream 3 weeks ago
CRBU. Under $2
👍️0
Monksdream Monksdream 1 month ago
CRBU under $2
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
CRBU READY TO BEAST
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
CRBU...NEW SCAN JUST GAVE ME THIS BIO
👍️0
Monksdream Monksdream 3 months ago
CRBU under $3
👍️0
Monksdream Monksdream 4 months ago
CRBU under $2
👍️0
Monksdream Monksdream 5 months ago
CRBU under $3
👍️0
Monksdream Monksdream 6 months ago
CRBU under $3
👍️0
jondoeuk jondoeuk 6 months ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 6 months ago
CRBU under $3
👍️0
Monksdream Monksdream 7 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 7 months ago
CRBU new 52 week low
👍️0
NY1972 NY1972 7 months ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 8 months ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 8 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 8 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 8 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 8 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 9 months ago
CRBU under $5
👍️0
stocksrising stocksrising 11 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 1 year ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 2 years ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 2 years ago
.
👍️0
trueblue trueblue 2 years ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 2 years ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 2 years ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 2 years ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 2 years ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 2 years ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 2 years ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 2 years ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 2 years ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
BIT
UC4NH7
Unicredit Bank
BIT
UC5CEU
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads